Bokf Na boosted its stake in shares of Shire PLC (NASDAQ:SHPG) by 8.7% during the third quarter, Holdings Channel reports. The institutional investor owned 5,407 shares of the biopharmaceutical company’s stock after buying an additional 433 shares during the period. Bokf Na’s holdings in Shire PLC were worth $1,048,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the stock. Quadrant Capital Group LLC raised its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the period. FTB Advisors Inc. raised its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the period. Seven Bridges Advisors LLC bought a new stake in Shire PLC during the third quarter valued at $123,000. Smithfield Trust Co. raised its stake in Shire PLC by 228.3% in the second quarter. Smithfield Trust Co. now owns 696 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 484 shares during the period. Finally, Integrated Wealth Management bought a new stake in Shire PLC during the second quarter valued at $128,000. Institutional investors and hedge funds own 22.75% of the company’s stock.
Shire PLC (NASDAQ:SHPG) traded down 1.38% during trading on Thursday, reaching $164.11. The company’s stock had a trading volume of 1,170,234 shares. The company’s 50 day moving average price is $0.00 and its 200-day moving average price is $0.00. Shire PLC has a 1-year low of $147.60 and a 1-year high of $209.22.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.21 by $0.04. Shire PLC had a net margin of 1.62% and a return on equity of 14.81%. The business earned $3.45 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the previous year, the business earned $3.24 earnings per share. The business’s quarterly revenue was up 108.6% on a year-over-year basis. On average, equities analysts anticipate that Shire PLC will post $12.95 earnings per share for the current fiscal year.
SHPG has been the subject of several analyst reports. HSBC lowered Shire PLC from a “buy” rating to a “hold” rating in a report on Monday, September 26th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Shire PLC in a report on Monday, October 24th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a report on Tuesday, September 27th. Shore Capital restated a “buy” rating on shares of Shire PLC in a report on Wednesday, September 28th. Finally, Goldman Sachs Group Inc. restated a “buy” rating on shares of Shire PLC in a report on Sunday, October 16th. Four analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $226.00.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).